CARDIOVASCULAR
CARE
Cardiovascular Care
SOLUTIONS
From routine lipid evaluations to complex genetic studies, LabCorp provides
an extensive menu of cardiovascular disease (CVD) testing to support the
spectrum of clinical scenarios that you face each day.
LabCorp’s medical and scientific professionals have constructed a comprehensive test menu to address
the complexities of cardiovascular care, and our ancillary tools and services help assimilate these tests
into your practice’s workflow.
Beyond a comprehensive test menu, LabCorp offers ancillary tools and services
to help enhance your practice, organization, quality measures, health information
technology, and patient care.
SERVICES AND TOOLS
LabCorp Link™ for test orders, results delivery, analytics, and trending
Cardiovascular Report for at-risk patients
Cardiovascular-specific Test Request Form for efficient test ordering
SERVICES AND TOOLS
A Result Report Like No Other
Available in PDF or HL7 format, the cardiovascular report presents a patient-specific, guideline-based analysis
of lipid test results in light of cardiovascular risk factors.
A patient friendly version of the report is available for patient consulting. Reports may also include Current
Laboratory Results, with visual cues relative to reference intervals, and Flow Sheets, which trend results over
eight future dates of service.
Generate the report for all patients when ordering a lipid panel, NMR LipoProfile® test, or either Lipid Cascade
option by completing the Cardiovascular Report Physician Request and Acknowledgement form. Alternatively,
order test 910385 in addition to a lipid panel, NMR LipoProfile test, or either Lipid Cascade option to generate
the color graphic PDF report as needed.
• Provides actionable information in support of clinical decision-making.
• Can be used to help educate and counsel patients.
rt
lts Repo
nt Resu
k Patie
Litholin
SERVICE
DATE OF
14
AN
PHYSICI
Sample
Physic
ian
d to
t intende
d are no ould
sh
ship an
t relation . The clinician
on
n-patien
1950
physicia d expert opini
n,
3/
tio
the
/0
tec
of
is
De
08
e an
ort
nel on
2; Conto k
in supp
evidenc
Litholink Patient Results Report
pert Pa
:811-8
enience dition to other
PHYSICIAN
NCEP Ex 2008; 31(4) rdiovascular ris
a conv
DATE OF SERVICE
ENDER
EN
GENDER
G
1
rt of the
PATIENT
vided as idelines in ad
Care
otic ca 00.DATE OF BIRTH
ird Repo al. Diabetes
are pro
Patient
l gu
PATIENT
eroscler
04/14/2014 Sample Physician
te’s Th
estions the nationa l patient.
M
ll et
Sample
uce ath 13; 00:000-0 08/03/1950
m
ua
od Institu 15); BrunzePatient
ent sugg
1 cu
rol to red
ion 20
treatm are derived fro and the individ ng, and Blo n 02-52Sample
ste
lat
d
ole
an
, Lu
tio
od ch idelines. Cir
on
ments ent. They
t of blo
publica
al opini
nal Heart
assess
These clinical judgm ntext of clinic MENT: Natio III) (2002. NIH the treatmen on Practice Gu
IMER:
on
SS
co
P
ents.
sk Force
DISCLA the physician’s within the R RISK ASSE in Adults (AT
ideline
ol is “good” and not known to
ific comm
tion Ta
on
AHA gu
n your heart health. Some cholester
on
ts o
cts
cts
ct
en-spec
varying effects
ol is the
replace this informati RDIOVASCULA od Cholesterol 2013 ACC/ Heart Associa
specim Cholesterol comes in different forms and has
r
arteries, this is non-HDL. LDL cholester
ic and
FOR CA t of High Blo Stone NJ et al. gy/American
conside
isease by clogging your arter
E
disease
cif
ol causes d
pe
NC
;
t-s
en
IDA
olo
19
tes
ol will lower your risk for disease.
o
disease, this is HDL. The rest of cholester
SEE GU
cause
cholester
d Treatm; 55(3):407-4 llege of Cardi
as any
“bad”
of
ll
an
vels
e
levels
le
r
u
ur
o
your
we
on
Lowering
ol.
s as
Evaluati Chem 2009 American Co
PATIEN
component of the non-HDL cholester
ol).
all result
largest
cholester
n
T
(“bad”
for
ol
the
Cli
rt
cholester
of
on-HDL
po
non-HDL
en
ort
et al.
component of the
Sa
s: a rep
bCorp Re
mpllevels
cause disease.
LDL cholesterol (LDL-C) is the largest
high
e Patie
your La
in adult
oll (not just LDL-C) and hig
ero
of).cholester
refer to
nt 1
types es
Please
(diabet
non-HDL is composed of many different
of heart disease risk other than just DATE OF BIR
Note:
a better estimate o
uivalent
BIRTH
DATE OF
20
04/14/
GENDER
M
Patient Results Summary
ent
ssessm
Risnsk A
r
la
u
c
estio
vas
Cardisio& Treatment Sugg
Flow Sh
o give
htt tto
TH
thought
k eq
(LDL-P)
GENDER
08/03/
CHD ris is another measure
eets
LDL particle number
ve one
19
re
95
The 8 mo
50
50
to hacholester
ol.
for futu
M
g s LDL
st recen or having a heart attack. The
appear
measurin
ed risk
heart disease
g hea
t lab res
patient
isk for developinLi
is
he rrisk
increasbe lowered depends on the
tes must
ults are
. Your
ica
LDL
pi
GH
your
ind
which
ds
HI
to
)
rep
level
The
/L
orted.
least
Analys
.78 mgfor heart disease, the lower your LDL goal.
k is at
(3
lt
ris
su
’s
risk
re your
nt
higher
ment
iac CRP
the patie ).
d.
rd
ss
ts
te
Ca
es
se
ica
45
risk.
sugg
ally ind
Risk As
ment).
tient's
mation ent (age over
if clinic
your pa
manage
al infor
Patient
aluation
modify
weight
le clinic k factor is pres
ider ev
ercise,
further
availab
ris
ia. Cons
TTot
(diet, ex
ota
used to
Current ional major
all
ry of
slipidem
status
may be
dit
ly histo d to the
Chol.
Ch
ndary dy
od lipid
results
One ad
co
l or fami
blo
er
juste
se
rk
al
e
tim
caus
persona should be ad untreated
bioma
hieve op
se can
y
such as
the
Cardiac cular events.
14
145
40
ble to ac
er disea
factors sity of therap an 50% from
as
astatin
and liv
s valua
al risk
en
lov
cardiov
ay
th
,
me
ion
int
s
ro
e
alw
mg
dit
e
les
th
0
are
13
1
39
tic synd
ent. Ad
s includ
30% to
ention,
tin 40-8
anges
Nephro
al judgm In CVD prev reduction of mg, pravasta line. Example
style ch
y.
d clinic
eutic life
tory an als of therap average LDL-C statin 20-40 treated base
Therap
va
dical his
an
e un
’s go
tegory
mg, sim
from th
upon me dify a patient lly results in
tin 5-10 50% or more
Risk Ca category based ns
mo
nera
sta
nt
ge
va
ion
y
tie
su
of
k
erap
rte
, ro
Pa
tient ris ing, and hype sity statin th tin 10-20 mg L-C reduction
one pa
LD
e)
Select e CHD, smok DERATE inten s): atorvasta an average
HIGH
se
elect on
ur
in
.
premat tient risk. MOlude (daily do rally results
egory (s
tin 20 mg
pa
ne
isk Cat IATE
level of Examples inc therapy ge and rosuvasta
R
t
en
tin
e.
ti
lin
y sta
0 mg
Pa
High
base
TERMED
100
intensit vastatin 40-8
IN
GH
HI
or
mg.
70
ses): at
(daily do
SULT
NT'S RE
= PATIE
LT
/ RESU
ANALYTE
LDL-C dL
mg/
71
L
non-HD dL
g/
100 m
LDL-P
ol/L
1035 nm
Lipid
ment
Assess
ent
Treatm ns
tio
Sugges
LOW
100
160
130
130
100
160
130
100
130
HDL-C
45
46
8.2
8
LDL-P
800
TG
147
135
AST
1000
w is 71
800
and no
was 66
is
normal, Cholesterol mg/dL.
190
LDL-C is
DL
1300
100
w is 71 mg/dL. Non-H and now is
ol/L.
no
1000
d
35 nm
an
93
al, was line high, 10
was 66 rol is
er
. norm
optimal,
nmol/L
1035
further gin
mg/dL LDL-P is bord
Choleste
L-C is
may be
Be
71 LD dL. Non-HDL d now is 100 L.
1600
lar risk vated LDL-P.
now is
an
g/
cu
ol/
d
m
r
as
93
an
nm
s
iov
to ele in use, conside
Card
was 66 rol is
timal, waceptable, 1035
ed due
ste
optimal,
dL. op
d
ac
increas statin already ve at least a
LDL-C is Non-HDL Chole w is 100 mg/
ment an h risk
LDL-P is
If
achie
.
e.
assess
statin.
mg/dL was 93 and no 35 nmol/L.
dose to from baselin
under hig
refer to tions
e
ing
as
as
is
Plan
re
es
10
Ple
Care
on
Your
tin
inc
sugg
optimal, acceptable,
sity sta
L reducti
ed
d
atment
50% LD e or high inten ot be tolerat
ment an h risk tre gory.
LDL-P is
e
nn
assess
cate
Moderat If statin ca es include us e
under hig
refer to
d.
Please t suggestions
preferre ed, alternativ zetimibe or bil
en
t (e
reas
treatm
en
inc
ag
or
ry.
cin.
estinal
catego
of an int estrant) or nia
qu
acid se
, PhD
S. Laks
Mitchell Director
ory
Laborat
14
D08973
CLIA# 14
70
100
DATE OF
SERVIC
PHYSICIA
04/14/ E
N
2014
Sample
16
18
1000
ALT
14
16
Lp(a)
Physicia
Total:HDLC
ratio
3.2
3.0
CK
57
41
25-D
11.5
Litholink, A LabCorp Company
2250 West Campbell Park Drive
Chicago,
Chicago Illinois 60612
TSH
2.710
30.0-100.
0 0.4504.500
80
800 338 4333 Telephone
86
866 361 7939 Facsimile
www.litholink.com
ww
6.13.2.19
Version:
Printed: 04/16/2014
3
3 of
Page:
DISC
DIS
SC
CL
CLA
LAI
AIM
AIME
M R:
R: Th
These
clin
li iical jud ER
e ass
asse
ess
ssmen
gment.
nts
ts and tre
They do me
evaluatio
atmen
not inc
nb
e
i lude
because
informati t suggestions
LabCorp
are
on such
does no
as family provided as a
t have ac
con
history,
cess to
persona venience and
the com
are neith
l history,
plete pa
Mitchell
tient me
er
or physi
S. Laks,
dical rec
cal findin comprehensive
PhD
Laborator
ord.
gs as wo
Litholin
y Direct
uld be ob nor intended to
k, A
or
CLIA# 14
rep
tained by
2250 We LabCorp Comp
D08973
the clinicialace the physicia
an
st
y
14
Campbel
n’s
n during
800 33
Chicago,
l Park Dri
8 4333
patient
Illinois 60
ve
Telephone
866
61
2
361 79
39 Facsim
www.lith
ile
olink.com
Version
:
6.13.2
Printed:
04/16/ .19
2014
Page:
2 of
3
Litholink
Patient
Apo-B:A
1
ratio
Results
Repo
Fasting
Yes
Yes
your physician should rely
ive treatment plan. Neither you nor
hensiv
ehe
re
diagnosis and comprehens
and Treatment of High Blood
that would be necessary for a complete
xp Panel on Detection, Evaluation
Expert
CEP E
CE
medical history or a physical examination
Institute’s Third Report of the NCEP
with TLC (2005. NIH
S: National Heart, Lung, and Blood
ou Guide to Lowering Your Cholesterol
Your
e’s Y
e’s
e’
solely on this guidance. REFERENCE
of the
Heart, Lung, and Blood Institute’s
NIH publication 02-5215); National
tic cardiovascular risk in adults: a report
(2002.
III)
atherosclero
(ATP
e
c
.19
u
d
e
reduce
Adults
re
in
to
cholesterol
3.2
Cholesterol
6.1
treatment of blood
:
al. 2013 ACC/AHA guideline on the
on
.
et
14
NJ
Stone
00:000-000
rsi
20
0
2013;
2
.
06-5235);
n
o
Ve
publication
04/16/ Circulation.
d:Guidelines.
3
Heart Association Task Force on Practice
nte
merican
Pri
Cardiology/A
of
College
of
American
1
hone
ge:
33 Telep le
Pa
43
8
800 33
Facsimi
y
1 7939
866 36
Compan
m
bCorp
olink.co
k, A La
rk Drive
www.lith
bell Pa
Litholin
st Camp
2
2250 We
ois 6061
Illin
,
Chicago
Mitchell S. Laks, PhD
Laboratory Director
CLIA# 14D0897314
n
Uric
Acid
AVAILABLE TESTS
THE CLINICAL CHALLENGE
Lipids and Lipoproteins
016873
Apolipoprotein A-1
216010
Apolipoprotein Assessment
167015
Apolipoprotein B
884247
NMR LipoProfile®
361946
Lipid Cascade With Reflex to Lipoprotein Particle
Assessment by NMR
363676
Lipid Cascade With Reflex to Apolipoprotein B
303756
Lipid Panel
343925
Lipid Profile With Non-HDL Cholesterol
368600
Familial Hypercholesterolemia (FH) Screen
235036
Lipoprotein Phenotyping Profile
120295
Low-density Lipoprotein Cholesterol (Direct)
818542
HDL-P, Total*
120188
Lipoprotein(a)
235010
Lipid Panel With LDL:HDL Ratio
221010
Lipid Panel With Total Cholesterol:HDL Ratio
Cardiovascular disease risk management
in at-risk patient populations
• The role of high levels of low-density lipoprotein (LDL) particles in the
development of cardiovascular disease (CVD) is well established.1
* This test was developed and its performance characteristics were determined by LipoScience.
It has not been cleared or approved by the food and Drug Administration.
The Lipid Cascade “Smart”
Testing Approach
Requiring a single blood draw, LabCorp’s Lipid
Cascade provides convenient, step-wise testing for
patient management.
Note: LDL values greater than 130 mg/dL
do not reflex.
panel
onal lipid rides,
Conventi
iglyce
lesterol, tr DL/HDL
Total cho
n, L
calculatio lation
HDL, LDL
u
-HDL calc
ratio, Non
Reflex*
• Elevated LDL drives entry of these atherogenic particles into the
arterial wall, accelerating development of CVD.1 The longer there is
exposure to elevated LDL, the greater the risk for clinical events.1
• Use of LDL-lowering therapies is a core strategy in managing CVD
risk.1 Once therapy is initiated, LDL values are monitored to assess
response to therapy and guide management decisions.
• Traditional low density lipoprotein-cholesterol (LDL-C) – calculated
or direct - is an estimate of LDL quantity based on the amount of
cholesterol contained in the LDL particles.1 However, the amount
of cholesterol per particle varies – particularly in patients with
type II diabetes, in statin-treated patients, and those with the
cardiometabolic risk (CMR) factors. LDL-C may be an unreliable
measure of LDL quantity for these at-risk patients in a
management setting.2,3
• LDL particle (LDL-P) can be measured by nuclear magnetic resonance
(NMR) or estimated by apolipoprotein B (Apo B). Neither NMR nor
Apo B quantifies LDL-P in a manner that depends on the amount of
cholesterol contained inside the LDL-P.
• LabCorp’s NMR LipoProfile test or Lipid Cascade options may help
inform patient management in these at-risk populations.
• Each Lipid Cascade option begins with a traditional lipid panel. If
the patient’s LDL-C value is < 130 mg/dL4, the traditional lipid panel
reflexes to LDL-P measurement by NMR or estimation by Apo B,
depending upon which Lipid Cascade option has been ordered.
ment
in assess LDL
te
ro
p
o
Lip
evaluate
by NMR tor assessment
number o p o B
by A
mg/dL
LDL < 130
erid es
If triglyc L
/d
/
> 400 mg
Reflex*
Direct LDL
/ddL
if <130 mg /
Reflex*
*Additional charge
AVAILABLE TESTS
Emerging Risk Factors & Inflammatory Markers
Heart Failure
500140
Heart Disease and Stroke Risk Profile
143000
NT-proBNP
120766
C-Reactive Protein (CRP), High Sensitivity
(Cardiovascular Risk Assessment)
004110
Galectin-3
140080
Galectin-3 With B-type Natriuretic Peptide
001610
Fibrinogen Activity
142005
Galectin-3 With NT-proBNP
117052
Fibrinogen Antigen
706994
Homocyst(e)ine, Plasma
140916
Interleukin-6
123240
Lipoprotein-associated Phospholipase A2
005207
Partial Thromboplastin Time (PTT), Activated
146787
Plasminogen Activator Inhibitor I (PAI-1) Activity
020321
005215
Sedimentation Rate, Modified Westergren
Prothrombin Time (PT) and Partial
Thromboplastin Time (PTT)
512103
Thrombotic Risk Profile, DNA Analysis
Clotting Risk Assessment
Diabetes
Genetic Assessment
004650
Adiponectin
160721
Antipancreatic Islet Cells
511710
Clopidogrel CYP2C19 Genotyping
001818
Glucose, Plasma
511460
Warfarin (P450 2C9 and VKORC1)
101000
Gestational Glucose Tolerance Screening and
Diagnostic Test (Two-hour, ADA 2011 Standards)
Therapy Monitoring
143008
Glutamic Acid Decarboxylase (GAD) Autoantibody
001453
Hemoglobin (Hb) A1c
102525
Hemoglobin (Hb) A1c With eAG
141531
IA2 Autoantibodies (Endocrine Sciences)
005199
Prothrombin Time (PT)
485199
Prothrombin Time (PT) (Serial Monitor)
007385
Digoxin
706705
Amiodarone
085662
Flecainide, Serum or Plasma
007831
Quinidine, Serum or Plasma
007864
Disopyramide, Serum or Plasma
AVAILABLE TESTS
Genetic Testing for Inherited
Structural and Electrical Conditions
Other
503935
Apo E Genotyping: Cardiovascular Risk
511238
Methylenetetrahydrofolate Reductase (MTHFR)
335884
Metabolic Syndrome Profile
004259
Thyroid-stimulating Hormone (TSH)
500140
Heart Disease and Stroke Risk Profile
Ambulatory ECG Monitoring Services
119530
Mobile Cardiovascular Telemetry (MCT)
999706
ECG Tracing and Computer Analysis
019372
Blood Pressure Monitoring
019380
Blood Pressure Unit—One-time Use and Analysis
009274
Holter Analysis Only
009324
Holter Recorder and Disposable Supplies One-time Use and Analysis
019323
Holter Hook-up/Disconnect by LabCorp
019331
Holter Cardiologist Overread
119503
Patient-activated Event Monitoring (PAEM),
Presymptom Cardiology Overread
119511
Patient-activated Event Monitoring (PAEM),
Hook-up/Disconnect by LabCorp
119420
Patient-activated Event Monitoring (PAEM),
Receipt of Transmissions
119180
ECG Computer Analysis Only
990333
ECG Cardiologist Overread Only, Adult
252651
Atrial Septal Defect (ASD) With Atrioventricular
Block (AVB): NKX2.5 (Full Gene Sequencing)
252405
Atrial Septal Defect (ASD) With Atrioventricular
Block (AVB): NKX2.5 (Known Mutation)
252880
Early-onset Coronary Heart Disease/Familial
Hypercholesterolemia: Three-gene Profile (LDLR,
APOB, PCSK9)
451422
GeneSeq®: Cardio Familial Cardiomyopathy Profile
451412
GeneSeq®: Cardio Familial Arrhythmia Profile
451432
GeneSeq®: Cardio Familial Aortopathy Profile
451441
GeneSeq®: Cardio Noonan Syndrome and Related
Conditions Profile
451402
GeneSeq®: Cardio Familial Congenital Heart
Disease Profile
451416
GeneSeq®: Cardio Early-onset Coronary Artery
Disease/Familial Hypercholesterolemia Profile
252419
Loeys-Dietz Syndrome (LDS): Two-gene Profile
(TGFBR1, TGFBR2) (Full Gene Sequencing)
252406
Marfan Syndrome (MFS): FBN1 (Full Gene
Sequencing)
252654
Marfan Syndrome (MFS): FBN1 (Known Mutation)
252409
Marfan Syndrome to Loeys-Dietz Syndrome Reflex
Profile (MFSLDS): FBN1TGFBR1,TGFBR2 (Full Gene
Sequencing)
252399
Pulmonic Stenosis: PTPN11 (Full Gene Sequencing)
252647
Pulmonic Stenosis: PTPN11 (Known Mutation)
252422
Thoracic Aortic Aneurysms and Dissections (TAAD):
Three-gene Profile (FBN1, TGFBR1, TGFBR2) (Full
Gene Sequencing)
Acute Ischemic Markers
120816
Creatine Kinase (CK), MB
001362
Creatine Kinase (CK), Total
010405
Myoglobin
140150
Troponin T
COMPLETING THE CONTINUUM OF CARDIOVASCULAR CARE
References
1. Toth, et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis, Volume 235, Issue 2,
August 2014. Pages 585–591.
2. Brunzell, JD, et al. Lipoprotein Management in Patients With Cardiometabolic Risk. Diabetes Care, Vol. 31, No. 4, Apr 2008. Pages 811-822.
3. AACE Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocrine Practice, Vol. 19 (Suppl 2), May/June 2013. Pages 1-48.
4. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program
(NCEP) Expert Panel. NIH Publication No. 01-3670, May 2001.
For the most current information regarding test options, including specimen requirements and
CPT codes, please consult the online Test Menu at www.LabCorp.com.
©2016 Laboratory Corporation of America® Holdings All rights reserved. L10222-1116-3